Participant flow18

How many started, completed or left each group, period by period.

1 to 18 of 18

Period	Milestone	Group	Participants
Overall Study	STARTED	Placebo	447
Overall Study	STARTED	Mirabegron 25 mg	441
Overall Study	STARTED	Mirabegron 50 mg	437
Overall Study	STARTED	Solifenacin 5 mg	434
Overall Study	STARTED	Solifenacin 5 mg + Mirabegron 25 mg	885
Overall Study	STARTED	Solifenacin 5 mg + Mirabegron 50 mg	883
Overall Study	COMPLETED	Placebo	404
Overall Study	COMPLETED	Mirabegron 25 mg	397
Overall Study	COMPLETED	Mirabegron 50 mg	387
Overall Study	COMPLETED	Solifenacin 5 mg	397
Overall Study	COMPLETED	Solifenacin 5 mg + Mirabegron 25 mg	802
Overall Study	COMPLETED	Solifenacin 5 mg + Mirabegron 50 mg	798
Overall Study	NOT COMPLETED	Placebo	43
Overall Study	NOT COMPLETED	Mirabegron 25 mg	44
Overall Study	NOT COMPLETED	Mirabegron 50 mg	50
Overall Study	NOT COMPLETED	Solifenacin 5 mg	37
Overall Study	NOT COMPLETED	Solifenacin 5 mg + Mirabegron 25 mg	83
Overall Study	NOT COMPLETED	Solifenacin 5 mg + Mirabegron 50 mg	85

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01972841/flow